A new kind of drugmaker is emerging to meet demand for lower-priced medicines by custom-making drugs, sparking pushback from federal health regulators and legal challenges from traditional pharmaceutical companies.
from WSJ.com: What's News US https://ift.tt/2CBV3tU
Cheap Custom-Made Versions of High-Cost Drugs Spur Backlash
0 comments:
Post a Comment